G-CSF mobilized autologous hematopoietic progenitor cells (HPC) may be collected by apheresis of patients with CGD and SCID for use in gene therapy trials. An adequate HPC apheresis harvest requires robust CD34+ cell mobilization. We retrospectively evaluated CD34+ cell mobilization and collection in 73 consecutive CGD and SCID patients and in 99 age, weight and G-CSF dose-matched healthy allogeneic controls. In subjects aged <20 years, day 5 peak pre-apheresis circulating CD34+ counts were significantly lower in CGD and SCID than in control patients; mean peak CD34 = 59, 64, and 81 cells/uL, respectively, p=0.05. The SCIDs had lower CD34 collection efficiency than CGDs and controls; mean efficiency 40%, 63% and 58%, respectively, p=0.001. In subjects >20 years, the CGDs had significantly lower CD34+ cell mobilization than controls; mean peak CD34 = 41 and 113 cells/uL, respectively, p<0.0001. In a multivariate analysis, lower sedimentation rate (ESR) at mobilization was significantly correlated with better CD34+ cell mobilization, p=0.007. In SCIDs, CD34 collection efficiency was strongly markedly reduced CD34 collection efficiencies were related to iron deficiency. In these patients, decreased red cell size and density due to iron deficiency may impair apheresis cell separation mechanics.
Introduction
Primary immunodeficiency disorders (PINDs) such as Chronic Granulomatous Disease (CGD) and Severe Combined Immune Deficiency (SCID) are genetic disorders of the innate and adaptive immune systems, respectively. The resulting clinical syndromes may be lifethreatening and in severe cases, patients present in childhood with recurrent infections, CGDassociated colitis, granulomas, and failure to thrive. Hematopoietic progenitor cell (HPC) transplantation from an HLA-matched sibling donor may be curative and is the treatment of choice in these conditions. Gene therapy may be a less toxic alternative if the genetic defect has been identified [1] .
Since the discovery of their engraftment capability more than two decades ago, cytokinestimulated peripheral blood progenitor cells (PBPCs) have surpassed bone marrow as the preferred source of stem cells for allogeneic and autologous transplantation [2, 3] . They have also been shown to be an efficient source of autologous cells for somatic gene therapy in CGD and SCID [4] [5] [6] . Compared to bone marrow aspiration, the relative ease of HPC collection by apheresis and larger CD34+ cell yields have made them the preferred cell source in gene therapy trials. Autologous PBPC collections may then be enriched by immune-affinity techniques and transduced with viral vectors carrying the missing genes to manufacture a clinically relevant dose of final product [1] .
Factors influencing HPC mobilization and methods to maximize progenitor cell yield have been studied extensively in the HPC transplantation setting. Parameters shown to significantly affect mobilization in healthy allogeneic PBPC donors include donor age, sex, race, and total G-CSF dose administered during mobilization. [7] . Donor characteristics may also affect the collection efficiency of HPC apheresis procedures. In an analysis of 793 consecutive healthy allogeneic donors undergoing HPC apheresis procedures, red cell microcytosis was noted to impair cell yields independent of pre-apheresis CD34+ cell counts [8] . Lastly, in the setting of autologous PBPC collection, mobilization failure (collection of less than 2 X 10 6 CD34+ cells/kg), commonly results from prior exposure to myelotoxic chemotherapy or radiation [9] [10] [11] [12] . CD34+ cell mobilization responses may be improved in donors with limited marrow reserve by adding plerixafor to G-CSF [13, 14] .
In patients with PINDs, chronic infections and/or inflammation can result in persistent leukocytosis. Inflammatory states have also been associated with increased endogenous G-CSF levels in mouse models [15] . Paradoxically, Sekhsaria et al. reported significantly impaired HPC mobilization in 18 CGD and 2 SCID patients compared to healthy controls [7] . They also noted the lack of an association between peak mobilized CD34+ cell counts and baseline absolute neutrophil counts among their subjects. The goal of the current study was to more fully characterize the CD34+ mobilization response to cytokine stimulation, in a larger cohort of CGD and SCID patients, and to identify and possibly mitigate the causes for poor CD34+ mobilization and collection yields in this population. We hoped in this manner to develop strategies to enable the collection of at least 5 x 10 6 CD34+ cells/kg, which is the typical targeted starting material for patients undergoing autologous HPC mobilization in gene therapy trials [16] .
Methods

Cases and matched controls
We performed a retrospective case-control study with 73 consecutive CGD (n=63) and SCID (n=10) subjects who underwent PBPC collection from April 1997 to October 2012. The control population consisted of healthy sibling or unrelated donors participating in our allogeneic transplant protocols during the same period, and were matched by age, weight, and total G-CSF dose received. All subjects gave informed consent in accordance with the Declaration of Helsinki and the IRB-approved transplantation protocols. Baseline demographic data were collected on all participants. Subjects were divided into pediatric (< 20 years) and adult (> 20 years) cohorts by age, based on prior observations that HPC mobilization responses differ in children versus adults [26] . A higher than usual cut-off for the definition of pediatric age was used due to the growth retardation and low weight of many of the subjects. The pediatric group consisted of CGD (n=38) and SCID (n=9) cases and a 1:1 ratio of healthy controls (n=47). The adult group included CGD (n=25) and SCID (n=1) cases and a 2:1 ratio of controls (n=52), who were matched with cases by age, sex, weight, and total G-CSF dose. The availability of a larger number of matched controls for the older age group allowed a 2:1 comparison; this was not possible in the younger age group.
Ancillary medications in patients
Interferon-gamma (IFN-g) (1.5 mg/kg 3 times weekly) was withheld 6 weeks in advance in all except 7 CGD patients who continued to take it during HPC mobilization. For CGD-colitis management, oral prednisone was given to 12% of patients at therapeutic doses (5-10 mg daily)
and to 42% at prophylactic doses (2.5-5 mg daily); 46% did not receive steroids during CD34+ PBPCs were collected by leukapheresis on day 5 of G-CSF. Three to thirty liters were processed per procedure based on the pre-apheresis CD34+ count as previously described [25] . Leukapheresis was performed with use of a CS-3000 Plus instrument (Fenwal Division, Baxter, Deerfield, IL). Prophylactic intravenous calcium and magnesium infusions were administered as previously described [17] . Collection efficiencies were calculated using the formula [25] :
CD34+ content in product (mean of pre-and post-apheresis CD34+ counts) x (volume processed)
Laboratory data
Complete blood counts were measured at baseline before G-CSF administration (pre-G-CSF), and before and after PBPC collection (post-G-CSF, pre-and post-apheresis). In the patient group, data were collected on erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and fibrinogen within a week of collection, as indicators of active inflammation and infection.
Serum ferritin and RBC indices were analyzed as indicators of iron deficiency. To determine whether RBC microcytosis was due to thalassemia trait or iron deficiency, an anemia index (Combined Cell Index -CCI) was calculated, as described previously [18] .
Statistics
Significance tests comparing 2 groups were conducted with two-tailed, non-paired t tests.
Multivariate analyses were performed using stepwise forward logistic regression, based on parameters of significance in univariate analysis, using a commercial statistics program (JMP, SAS Institute Inc.,Cary, NC). Proportions between 2 or more groups were compared using twotailed Fisher exact test or chi-square analyses, respectively.
Results
Subject demographics and CD34+ cell yield
Demographic characteristics for subjects are shown in Table 1 . The patients were predominantly Caucasian (CGD=78%; SCID=100%) and male (CGD=95%; SCID=100%). SCID were significantly younger (19 vs.13 years, p<0.05) and weighed less than the CGD patients (46 vs. 33 kg, p<0.04). When analyzed by age groups, the CGD, SCID and control subjects under 20 years were similar in mean age, BMI and total G-CSF dose administered (these parameters were matched a priori)( Table 2 ). There were significantly more non-Caucasians and females among the controls. Baseline laboratory data, were similar in the 3 groups, with the exception of Hemoglobin (lower in cases than controls) and ferritin levels (markedly lower among SCID than CGD subjects: 20 vs.134 ng/mL, p<0.02). The mean peak circulating CD34+ cell count just prior to apheresis was significantly lower among cases than controls (60, 64 and 81 cells/uL in CGD, SCID and controls, respectively, p=0.05). In SCID but not CGD subjects, CD34+ cell apheresis collection efficiencies were significantly lower than in healthy controls (63, 40 and 58% in CGD, SCID and control, respectively, p=0.001).
In the adult cohort (>20 years old), CGD and control subjects were similar in age, sex and total G-CSF dose received (matched a priori) ( Table 3 ). The two subject groups differed by race and weight. Hemoglobin and MNC counts were significantly lower in CGD than control subjects.
Mean peak circulating pre-apheresis CD34+ cell counts were significantly lower among the CGD than control subjects (41 vs.113 cells/uL, p<0.0001). CD34+ apheresis collection efficiency was similar in the two groups (67 vs. 59%, p=0.07).
CD34+ cell counts: G-CSF dose alone or with plerixafor
Among cases, a higher G-CSF dose was only associated with a trend toward better mobilization (mean peak CD34+ count at G-CSF 10 ug/kg = 40/uL and at G-CSF 16 ug/kg = 63/uL, p=0.07).
Within each age category, when stratified by G-CSF dose, cases mobilized more poorly than controls at both 10 ug/kg and 16ug/kg (Tables 4 and 5 ). As the pre-apheresis circulating CD34+
cell count is the strongest predictor of CD34+ cell yield, the CD34+ cell yield per liter processed was also significantly lower among cases than controls.
Mean day 4 circulating CD34+ cell counts in the patients who received G-CSF plus plerixafor were significantly lower than day 4 counts in patients receiving G-CSF alone (14 ± 6 vs. 41 ± 33 cells/uL, p<0.001). Day 5 counts increased 3 to 4-fold in patients who received supplemental plerixafor, such that day 5 counts were significantly higher in the G-CSF plus plerixafor group than in the G-CSF alone group (76 ± 36 vs. 49 ± 39 cells/uL, p<0.03) (Fig.1) .
Factors affecting CD34+ cell mobilization
In univariate analysis of patients who received G-CSF alone, higher CD34+ cell counts on day 4
and day 5 of mobilization were strongly correlated with greater subject weight, higher baseline platelet count, lower ESR at mobilization, higher total dose of G-CSF received. Among controls, higher peak CD34+ counts were similarly associated with weight, platelet counts and G-CSF dose, but in addition, male sex and higher baseline MNC count were also significant contributors. In multivariate regression analysis, only a higher baseline platelet count and lower ESR at time of mobilization remained significantly correlated with CD34+ cell mobilization in the patients, p=0.01 and 0.007, respectively; total G-CSF no longer made a significant contribution.
In contrast, in multivariate analysis of the control group, male sex, higher baseline platelets and
MNCs and higher total G-CSF dose remained significantly correlated with mobilization efficacy.
Mean ESR was significantly higher among subjects with active infection and/or CGD-associated colitis compared to those without these events (40 vs. 16 mm/hr, p=0.0001). Although 26% and 37% of patients had clinical evidence of active CGD-associated colitis, fungal/bacterial infections, no correlation could be established between these clinical diagnoses and peak CD34+ cell counts. Interferon use in the peri-collection period among the 7 CGD subjects, steroid use and antibiotic administration correlated poorly with mobilization in the initial analysis and were excluded from the final multivariate model.
Factors affecting CD34+ cell collection efficiency
Multivariate analysis of all subjects showed no effect of CBC parameters and ESR, on CD34+ to what was previously reported [8] .
Multiple day collections
Thirty-four of 73 patients underwent repeat collections. Mean pre-apheresis CD34+ count on the second day of apheresis, after an additional dose of G-CSF on day 6, was 24% lower than on day 5 (34 vs. 45 CD34+ cells/uL, p=0.1). In 4 patients who underwent a third consecutive PBPC collection, mean pre-procedure CD34+ counts decreased to 18.5 cells/uL on the third day of apheresis.
Discussion
We demonstrate, in the largest population of such subjects studied to date, that patients with CGD and SCID undergoing HPC collection for gene therapy trials are characterized by significantly less robust CD34+ mobilization than healthy age-and weight-matched controls. In the CGD population, a 27 to 37% lower peak CD34 response to conventional doses of filgrastim was seen in the <age 20 and >age 20 cohorts, respectively, compared with controls. In the SCID patients, a 21% decrease in peak CD34 response compared to controls was seen. Our control groups demonstrated a more vigorous peak CD34+ mobilization response, 81 cells/uL, than that previously reported in healthy donors [7] , possibly because of the younger population of the allogeneic donors included in this case-control study. Our patient population consisted largely of children and young adults with lower than average body mass indices due to chronic illness; we attempted to eliminate the possible confounding effects of age, BMI, sex, and G-CSF dose by selecting matched controls. Our study also provides novel information on correlates of donor and procedural parameters that influence CD34 mobilization responses in patients with CGD and SCID. Higher baseline platelet count, perhaps reflecting more healthy marrow reserve [7, 19] , was strongly correlated with better CD34 mobilization, whereas higher ESR was associated with poor mobilization responses. In contrast to the control group, male gender, increased weight and BMI, and higher total G-CSF dose were not associated with better CD34 mobilization.
The presence of active infection/inflammation at collection, as evidenced by an elevated ESR, appeared to be a unique contributor to decreased CD34+ cell mobilization among CGD and SCID subjects, despite similar levels of G-CSF-associated leukocytosis in both patient and control groups. The role of inflammatory markers such as TNF-a, IFN-g, IL-2, IL-6, and endogenous G-CSF in stem cell mobilization has been evaluated mainly in the setting of bone marrow failure syndromes such as aplastic anemia, and yielded mixed results [20, 21] . PINDs may represent an informative setting in which to study pathways involved in cytokine-mediated marrow suppression. From a clinical perspective, collection yields may be improved if patients undergo mobilization after maximum infection control, when possible. The value of using a higher G-CSF dose in the setting of persistent infection is questionable. It is likely that endogenous increases in G-CSF levels under these conditions may result in tachyphylaxis and inadequate response to exogenous G-CSF [15] . IFN-g administration did not appear to influence CD34+ cell mobilization in our study, although it has previously been reported to impair mobilization [21, 22] .
Preemptively adding plerixafor to G-CSF, based on circulating CD34+ count measurements obtained the day prior to apheresis, appears to be an effective approach to mitigating low CD34 mobilization responses in patients with active infections. Plerixafor, approved for use in HPC mobilization in patients with multiple myeloma and lymphoma, is associated with engraftment pace and durability similar to that seen following G-CSF mobilization alone, despite geneexpression profiling differences in cells mobilized with filgrastim vs. plerixafor alone [13, 23] . The effect of plerixafor on gene transduction efficiencies, engraftment and transgene expression has not been fully characterized. Initial investigations suggest that progenitor cells collected with plerixafor have unique transduction and gene expression characteristics, especially with use of newer lentiviral vector protocols [24] .
Among SCID subjects, in addition to poor mobilization, we noted markedly reduced CD34+ cell collection efficiencies. We have previously noted that low MCV values due to iron deficiency can markedly impair the efficacy of MNC collection by apheresis even in subjects who mobilize well. Variability in red cell size and density, as evidenced by MCV and MCH values, can affect optimal optical interpretation and automated sampling of the white blood cell layer by the apheresis device. Our SCID subjects had significantly lower Hemoglobin and MCV levels than healthy controls, had profoundly low ferritin levels, and had a CCI characteristic of iron deficiency. They had iron deficiency anemia. In contrast, the mean ferritin level in the CGD group was elevated, suggesting that low Hemoglobin in this group was due to inflammation and the anemia of chronic disease, and the CGD group was characterized by normal CD34 collection efficiency during apheresis. It is likely that vigorous, timely oral or parenteral iron replacement in SCID subjects with microcytosis due to iron deficiency would result in markedly improved apheresis collection efficiencies, and we have seen this in our practice.
Nearly 50% of patients with poor CD34 mobilization responses required more than one procedure to collect the targeted CD34 dose of at least 10 million CD34+ cells per kg, despite use of larger volumes processed (as many as 8 blood volumes per procedure). In these patients who underwent multiple consecutive daily collections, pre-apheresis CD34+ counts decreased with each collection, despite additional G-CSF doses. The majority of patients achieved targeted cell dose collections after the second procedure.
In summary, cytokine-assisted CD34+ cell mobilization from the marrow into the blood in patients with primary immunodeficiency disorders is significantly impaired compared with that in healthy allogeneic donors. Selective marrow suppression by inflammatory signals or possibly diminished marrow CD34+ cell reserve due to stem cell utilization for repair in these chronic conditions, may be responsible for the poor mobilization responses. Tachyphylaxis to exogenous cytokine stimulation due to increased endogenous G-CSF secretion may further impair mobilization response. A low baseline platelet count, high ESR, and microcytosis due to iron deficiency can be used to predict those subjects at greatest risk of poor mobilization. The two most effective strategies to mitigate poor mobilization and inefficient apheresis collection in this population include prospective correction of iron deficiency and careful monitoring of preapheresis CD34+ cell counts to determine which patients would benefit from supplemental plerixafor. Strategies used in other situations, such as a higher G-CSF dose, were ineffective in this population. Lastly, vigorous prospective control of infection/inflammatory states, which act as marrow stressors, may improve mobilization. 
